

Eric Lawitz

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4423183/publications.pdf>

Version: 2024-02-01

69
papers

19,015
citations

50244

46
h-index

95218

68
g-index

69
all docs

69
docs citations

69
times ranked

9514
citing authors

#	ARTICLE	IF	CITATIONS
1	Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection. <i>New England Journal of Medicine</i> , 2013, 368, 1878-1887.	13.9	1,605
2	Boceprevir for Previously Treated Chronic HCV Genotype 1 Infection. <i>New England Journal of Medicine</i> , 2011, 364, 1207-1217.	13.9	1,538
3	Telaprevir for Retreatment of HCV Infection. <i>New England Journal of Medicine</i> , 2011, 364, 2417-2428.	13.9	1,466
4	Ledipasvir and Sofosbuvir for Previously Treated HCV Genotype 1 Infection. <i>New England Journal of Medicine</i> , 2014, 370, 1483-1493.	13.9	1,241
5	Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis. <i>New England Journal of Medicine</i> , 2014, 370, 1879-1888.	13.9	1,080
6	Daclatasvir plus Sofosbuvir for Previously Treated or Untreated Chronic HCV Infection. <i>New England Journal of Medicine</i> , 2014, 370, 211-221.	13.9	1,065
7	Sofosbuvir for Hepatitis C Genotype 2 or 3 in Patients without Treatment Options. <i>New England Journal of Medicine</i> , 2013, 368, 1867-1877.	13.9	992
8	Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. <i>Lancet, The</i> , 2019, 394, 2184-2196.	6.3	818
9	Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naïve patients: the COSMOS randomised study. <i>Lancet, The</i> , 2014, 384, 1756-1765.	6.3	751
10	Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection. <i>New England Journal of Medicine</i> , 2015, 373, 2608-2617.	13.9	740
11	Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis. <i>New England Journal of Medicine</i> , 2015, 373, 2618-2628.	13.9	692
12	All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. <i>Hepatology</i> , 2015, 61, 1127-1135.	3.6	598
13	Preliminary Study of Two Antiviral Agents for Hepatitis C Genotype 1. <i>New England Journal of Medicine</i> , 2012, 366, 216-224.	13.9	580
14	Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naïve and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial. <i>Lancet, The</i> , 2014, 383, 515-523.	6.3	522
15	Glecaprevir and Pibrentasvir in Patients with HCV and Severe Renal Impairment. <i>New England Journal of Medicine</i> , 2017, 377, 1448-1455.	13.9	348
16	Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naïve patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial. <i>Lancet Infectious Diseases, The</i> , 2013, 13, 401-408.	4.6	313
17	Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial. <i>Lancet, The</i> , 2015, 385, 1075-1086.	6.3	281
18	Exploratory Study of Oral Combination Antiviral Therapy for Hepatitis C. <i>New England Journal of Medicine</i> , 2013, 368, 45-53.	13.9	271

#	ARTICLE	IF	CITATIONS
19	Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial. <i>Lancet</i> , The, 2013, 381, 2100-2107.	6.3	265
20	Phase 2b Trial of Interferon-free Therapy for Hepatitis C Virus Genotype 1. <i>New England Journal of Medicine</i> , 2014, 370, 222-232.	13.9	262
21	Efficacy of Direct-Acting Antiviral Combination for Patients With Hepatitis C Virus Genotype 1 Infection and Severe Renal Impairment or End-Stage Renal Disease. <i>Gastroenterology</i> , 2016, 150, 1590-1598.	0.6	253
22	Simeprevir With Peginterferon and Ribavirin Leads to High Rates of SVR in Patients With HCV Genotype 1 Who Relapsed After Previous Therapy: A Phase 3 Trial. <i>Gastroenterology</i> , 2014, 146, 1669-1679.e3.	0.6	239
23	Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: An integrated safety and efficacy analysis. <i>Hepatology</i> , 2015, 62, 79-86.	3.6	232
24	Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized Trials. <i>Gastroenterology</i> , 2017, 153, 113-122.	0.6	215
25	Infrequent Development of Resistance in Genotype 1 Hepatitis C Virus-Infected Subjects Treated With Sofosbuvir in Phase 2 and 3 Clinical Trials. <i>Clinical Infectious Diseases</i> , 2014, 59, 1666-1674.	2.9	199
26	Prevalence of Resistance-Associated Substitutions in HCV NS5A, NS5B, or NS3 and Outcomes of Treatment With Ledipasvir and Sofosbuvir. <i>Gastroenterology</i> , 2016, 151, 501-512.e1.	0.6	192
27	Concordance of sustained virological response 4, 12, and 24 weeks post-treatment with sofosbuvir-containing regimens for hepatitis C virus. <i>Hepatology</i> , 2015, 61, 41-45.	3.6	173
28	Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: A phase 3 study (OPTIMIST-2). <i>Hepatology</i> , 2016, 64, 360-369.	3.6	166
29	Grazoprevir and elbasvir plus ribavirin for chronic HCV genotype-1 infection after failure of combination therapy containing a direct-acting antiviral agent. <i>Journal of Hepatology</i> , 2015, 63, 564-572.	1.8	132
30	Sofosbuvir with peginterferon-ribavirin for 12 weeks in previously treated patients with hepatitis C genotype 2 or 3 and cirrhosis. <i>Hepatology</i> , 2015, 61, 769-775.	3.6	114
31	Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection. <i>New England Journal of Medicine</i> , 2013, 369, 678-679.	13.9	108
32	Grazoprevir, Elbasvir, and Ribavirin for Chronic Hepatitis C Virus Genotype 1 Infection After Failure of Pegylated Interferon and Ribavirin With an Earlier-Generation Protease Inhibitor: Final 24-Week Results From C-SALVAGE: Table 1.. <i>Clinical Infectious Diseases</i> , 2016, 62, 32-36.	2.9	92
33	Characterization of Hepatitis C Virus Resistance from a Multiple-Dose Clinical Trial of the Novel NS5A Inhibitor GS-5885. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 6333-6340.	1.4	89
34	Minimal impact of sofosbuvir and ribavirin on health related quality of life in Chronic Hepatitis C (CH-C). <i>Journal of Hepatology</i> , 2014, 60, 741-747.	1.8	88
35	Effects of Sofosbuvir-Based Treatment, With and Without Interferon, on Outcome and Productivity of Patients With Chronic Hepatitis C. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 1349-1359.e13.	2.4	87
36	L159F and V321A Sofosbuvir-Associated Hepatitis C Virus NS5B Substitutions. <i>Journal of Infectious Diseases</i> , 2016, 213, 1240-1247.	1.9	86

#	ARTICLE	IF	CITATIONS
37	A phase 2a trial of 12-week interferon-free therapy with two direct-acting antivirals (ABT-450/r, Tj ETQq1 1 0.784314 rgBT /Overlock 10 2013, 59, 18-23.	1.8	84
38	Post-treatment resistance analysis of hepatitis C virus from phase II and III clinical trials of ledipasvir/sofosbuvir. <i>Journal of Hepatology</i> , 2017, 66, 703-710.	1.8	81
39	Safety and Efficacy of Elbasvir/Grazoprevir in Patients With Hepatitis C Virus Infection and Compensated Cirrhosis: An Integrated Analysis. <i>Gastroenterology</i> , 2017, 152, 1372-1382.e2.	0.6	79
40	Patient-reported outcomes in chronic hepatitis C patients with cirrhosis treated with sofosbuvir-containing regimens. <i>Hepatology</i> , 2014, 59, 2161-2169.	3.6	77
41	Efficacy and Safety of Ombitasvir, Paritaprevir, and Ritonavir in an Open-Label Study of Patients With Genotype 1b Chronic Hepatitis C Virus Infection With and Without Cirrhosis. <i>Gastroenterology</i> , 2015, 149, 971-980.e1.	0.6	77
42	Ledipasvir- sofosbuvir plus ribavirin for patients with genotype 1 hepatitis C virus previously treated in clinical trials of sofosbuvir regimens. <i>Hepatology</i> , 2015, 61, 1793-1797.	3.6	76
43	Short-duration treatment with elbasvir/grazoprevir and sofosbuvir for hepatitis C: A randomized trial. <i>Hepatology</i> , 2017, 65, 439-450.	3.6	71
44	Sofosbuvir- velpatasvir- voxilaprevir with or without ribavirin in direct-acting antiviral- experienced patients with genotype 1 hepatitis C virus. <i>Hepatology</i> , 2017, 65, 1803-1809.	3.6	53
45	Daclatasvir Plus Peginterferon and Ribavirin Is Noninferior to Peginterferon and Ribavirin Alone, and Reduces the Duration of Treatment for HCV Genotype 2 or 3 Infection. <i>Gastroenterology</i> , 2015, 148, 355-366.e1.	0.6	49
46	EDP-305 in patients with NASH: A phase II double-blind placebo-controlled dose-ranging study. <i>Journal of Hepatology</i> , 2022, 76, 506-517.	1.8	49
47	Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients With Genotype 1 Hepatitis C Virus Infection in an Open-Label, Phase 2 Trial. <i>Gastroenterology</i> , 2016, 151, 893-901.e1.	0.6	46
48	Efficacy and safety of glecaprevir/pibrentasvir in renally impaired patients with chronic HCV infection. <i>Liver International</i> , 2020, 40, 1032-1041.	1.9	44
49	Exploratory trial of ombitasvir and ABT-450/r with or without ribavirin for HCV genotype 1, 2, and 3 infection. <i>Journal of Infection</i> , 2015, 70, 197-205.	1.7	35
50	The emergence of NS5B resistance associated substitution S282T after sofosbuvir-based treatment. <i>Hepatology Communications</i> , 2017, 1, 538-549.	2.0	35
51	Development of sofosbuvir for the treatment of hepatitis C virus infection. <i>Annals of the New York Academy of Sciences</i> , 2015, 1358, 56-67.	1.8	31
52	Sofosbuvir plus ribavirin and sofosbuvir plus ledipasvir in patients with genotype 1 or 3 hepatitis C virus and severe renal impairment: a multicentre, phase 2b, non-randomised, open-label study. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 918-926.	3.7	28
53	Safety, Pharmacokinetics and Pharmacodynamics of the Oral Toll-Like Receptor 7 Agonist GS-9620 in Treatment-Naive Patients with Chronic Hepatitis C. <i>Antiviral Therapy</i> , 2015, 20, 699-708.	0.6	26
54	Characterization of HCV Resistance from a 3-Day Monotherapy Study of Voxilaprevir, a Novel Pangenotypic NS3/4A Protease Inhibitor. <i>Antiviral Therapy</i> , 2018, 23, 325-334.	0.6	24

#	ARTICLE	IF	CITATIONS
55	Daclatasvir + asunaprevir + beclabuvir ± ribavirin for chronic HCV genotype 1 infected treatment-naïve patients. <i>Liver International</i> , 2016, 36, 189-197.	1.9	23
56	Adherence to pan-genotypic glecaprevir/pibrentasvir and efficacy in HCV infected patients: A pooled analysis of clinical trials. <i>Liver International</i> , 2020, 40, 778-786.	1.9	22
57	Glecaprevir + pibrentasvir (ABT493 + ABT-530) for the treatment of Hepatitis C. <i>Expert Review of Gastroenterology and Hepatology</i> , 2018, 12, 9-17.	1.4	20
58	Sa2073 SVR4 Results of a Once Daily Regimen of Simeprevir (TMC435) Plus Sofosbuvir (GS-7977) With or Without Ribavirin (RBV) in HCV GT 1 Null Responders. <i>Gastroenterology</i> , 2013, 144, S-374-S-375.	0.6	18
59	Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir in Patients With Hepatitis C Virus Genotype 1 or 4 Infection and Advanced Kidney Disease. <i>Kidney International Reports</i> , 2019, 4, 257-266.	0.4	15
60	Safety and efficacy of a fixed-dose combination regimen of grazoprevir, ruzasvir, and uprifosbuvir with or without ribavirin in participants with and without cirrhosis with chronic hepatitis C virus genotype 1, 2, or 3 infection (C-CREST-1 and C-CREST-2, part B): two randomised, phase 2, open-label trials. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 814-823.	3.7	14
61	Efficacy and safety of a two-drug direct-acting antiviral agent regimen ruzasvir 180Âmg and uprifosbuvir 450Âmg for 12Âweeks in adults with chronic hepatitis C virus genotype 1, 2, 3, 4, 5 or 6. <i>Journal of Viral Hepatitis</i> , 2019, 26, 1127-1138.	1.0	10
62	High Sustained Virologic Response Rates of Glecaprevir/Pibrentasvir in Patients With Dosing Interruption or Suboptimal Adherence. <i>American Journal of Gastroenterology</i> , 2021, 116, 1896-1904.	0.2	8
63	Next-Generation Regimens. <i>Clinics in Liver Disease</i> , 2015, 19, 707-716.	1.0	6
64	Efficacy and safety of ruzasvir 60Âmg and uprifosbuvir 450Âmg for 12Âweeks in adults with chronic hepatitis C virus genotype 1, 2, 3, 4 or 6 infection. <i>Journal of Viral Hepatitis</i> , 2019, 26, 675-684.	1.0	6
65	Antiviral response and resistance analysis of treatment-naïve HCV infected patients receiving multiple doses of the NS3 protease inhibitor GS-9256. <i>Antiviral Research</i> , 2017, 140, 151-157.	1.9	5
66	Simeprevir, daclatasvir, and sofosbuvir for hepatitis C virus infected patients: Long-term follow-up results from the open-label, Phase II IMPACT study. <i>Health Science Reports</i> , 2020, 3, e145.	0.6	4
67	Oligonucleotide-Based Therapeutics: An Emerging Strategy for the Treatment of Chronic Liver Diseases. <i>Hepatology</i> , 2021, 73, 1581-1593.	3.6	4
68	Resistance Analysis of a 3-Day Monotherapy Study with Glecaprevir or Pibrentasvir in Patients with Chronic Hepatitis C Virus Genotype 1 Infection. <i>Viruses</i> , 2018, 10, 462.	1.5	2
69	Real World Experience in the Era of First Generation Protease Inhibitors in the Treatment of Hepatitis C. <i>Current Hepatitis Reports</i> , 2013, 12, 189-194.	0.3	0